株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のトランスレーショナル再生医療市場の見通し:2017年〜2027年

Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

発行 Visiongain Ltd 商品コード 209071
出版日 ページ情報 英文 316 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=144.82円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界のトランスレーショナル再生医療市場の見通し:2017年〜2027年 Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies
出版日: 2017年04月05日 ページ情報: 英文 316 Pages
概要

世界のトランスレーショナル再生医療市場は、2016年の58億米ドルから、2021年には145億米ドルまで拡大すると予測されています。

当レポートでは、世界のトランスレーショナル再生医療市場について調査分析し、市場予測、地域別の市場予測、二次市場の予測、主要製品、主要企業、SWOT分析、ファイブフォース分析など、体系的な情報を提供しています。

第1章 調査概要

第2章 トランスレーショナル再生医療のイントロダクション

  • 再生医療とは
  • トランスレーショナル再生医療:市場内訳
    • 幹細胞治療
    • 再生医療
    • 遺伝子治療
  • 再生医療に対するその他のアプローチ
  • 再生医療の規制
    • 欧州
    • 米国
  • 臨床試験の段階
  • 市場定義

第3章 トランスレーショナル再生医療市場

  • 世界のトランスレーショナル再生医療:市場概要
  • 世界のトランスレーショナル再生医療市場
  • 世界のトランスレーショナル再生医療:市場予測

第4章 幹細胞治療:主な用途

  • 世界の幹細胞治療市場
  • 幹細胞治療:世界市場予測
  • AlloStem (AlloSource)
  • Osteocel Plus (NuVasive)
  • Trinity ELITE、Trinity Evolution (Orthofix)
  • PureGen (AlphaTec Spine)
  • その他の承認幹細胞治療製品
  • 幹細胞治療の開発パイプライン
  • ChondroCelect (TiGenix BV)
  • 幹細胞治療市場:促進要因・抑制要因

第5章 再生医療:主な用途

  • 世界の再生医療市場
  • 再生医療:世界市場予測
  • 創傷修復・治癒における再生医療
  • 軟骨修復における再生医療
  • その他の利用可能な再生医療
  • 再生医療:開発パイプライン
  • 臓器移植と再生医療の将来見通し
  • 再生医療製品市場:促進要因・抑制要因

第6章 遺伝子治療:主な用途

  • 世界の遺伝子治療市場
  • 遺伝子治療:世界市場予測
  • 現在利用可能な遺伝子治療製品
  • 遺伝子治療の開発パイプライン
  • 遺伝子治療市場:促進要因・抑制要因

第7章 トランスレーショナル再生医療の主要国市場

  • トランスレーショナル再生医療市場:地域別
  • 主要国市場:予測
  • 地域別のトランスレーショナル再生医療市場:分析と予測
  • 米国:最大の市場
  • 欧州:断片的市場
  • アジア太平洋地域:規制情勢
  • その他の地域

第8章 トランスレーショナル再生医療市場における主要企業

  • トランスレーショナル再生医療:革新の温床
  • Alphatec Spine
  • Anterogen
  • Athersys
  • Avita Medical
  • AxoGen
  • Medipost
  • Mesoblast
  • NuVasive
  • Ocata Therapeutics
  • Organogenesis
  • Osiris Therapeutics
  • Pharmicell
  • Regenerys
  • TiGenix
  • UniQure
  • Vericel Corporation

第9章 世界のトランスレーショナル再生医療市場の定性分析

  • 市場に影響を与える要因
  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ファイブフォース分析

第10章 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0183

The translational regenerative medicine market has been undergoing considerable changes over the last few years. There are a number of therapies that have been launched into the market over the last few years. Stem cell therapies are being developed constantly and these are targeted at various indications, from the more common cardiovascular conditions to rarer orphan indications.

The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 316-page report you will receive 107 tables and 66 figures - all unavailable elsewhere.

The 316-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Translational Regenerative Medicine market forecasts from 2017-2027
  • Translational Regenerative Medicine regional market forecasts from 2017-2027, covering:
    • United States
    • Europe
    • Asia-Pacific
    • Rest of the World
  • Global Translational Regenerative Medicine submarket forecasts from 2017-2027 covering:
    • Stem Cell Therapies
    • Tissue Engineered Products
    • Gene Therapies
  • Forecasts from 2017-2027 of the leading products in the Global Translational Regenerative Medicine market:
    • Osteocel Plus
    • Trinity ELITE
    • TEMCELL /Prochymal
    • Apligraf
    • Dermagraft
    • Epifix
    • ReCell
    • Neovasculgen
    • Glybera (alipogene tiparvovec)
    • IMLYGIC (talimogene laherparepvec)
  • Assessment of the leading companies in the Global Translational Regenerative Medicine market:
    • Alphatec Spine
    • Anterogen
    • Athersys
    • Avita Medical
    • AxoGen
    • Medipost
    • Mesoblast
    • NuVasive
    • Ocata Therapeutics
    • Organogenesis
    • Osiris Therapeutics
    • Pharmicell
    • Regenerys
    • TiGenix
    • UniQure
    • Vericel Corporation
  • SWOT and Porter's Five Force analysis of the translational regenerative medicine market

Visiongain's study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.

Buy our report today Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Translational Regenerative Medicine: Market Overview
  • 1.2. Global Translational Regenerative Medicine Market Definition and Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered By This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions(FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. An Introduction to Translational Regenerative Medicine

  • 2.1. What Is Regenerative Medicine?
    • 2.1.1. Translational Regenerative Medicine - From Bench to Bedside
  • 2.2. Translational Regenerative Medicine - Market Breakdown
    • 2.2.1. Stem Cell Therapy - Marketable Differentiation and Specialization
      • 2.2.1.1. How Embryonic Stem Cells(ESCs) Entered the Fray
      • 2.2.1.2. Classifying Stem Cells by Potency
      • 2.2.1.3. Stem Cells Categories: ESCs, SSCs, iPSCs
      • 2.2.1.4. Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
      • 2.2.1.5. Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
    • 2.2.2. Tissue Engineering - In Vitro Manipulation for Therapeutic Purposes
    • 2.2.3. Gene Therapies
      • 2.2.3.1. Harnessing Infectivity: Viral Vectors in Gene Therapy
  • 2.3. Other Approaches to Regenerative Medicine
    • 2.3.1. Small Molecules and Proteins - Scaffold-Based Delivery of Signaling Molecules
    • 2.3.2. Cosmetic Applications of Regenerative Medicine
  • 2.4. Regulation of Regenerative Medicine
    • 2.4.1. Regulation of Regenerative Medicine Products in Europe
    • 2.4.2. Regulation of Regenerative Medicine Products in the US
  • 2.5. The Phases of Clinical Trials
  • 2.6. Market Definition
    • 2.6.1. Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2017-2027

  • 3.1. Global Translational Regenerative Medicine: Market Overview
    • 3.1.1. Segments within the Global Translational Regenerative Medicine Market
  • 3.2. The Global Translational Regenerative Medicine Market in 2016 and 2017
  • 3.3. Global Translational Regenerative Medicine: Market Forecast 2017-2027
    • 3.3.1. Market Sectors That Will Drive Translational Regenerative Medicine Growth
    • 3.3.2. Global Translational Regenerative Medicine Market - Changing Market Shares by Sector 2017-2027
    • 3.3.3. Global Translational Regenerative Medicine Market - Current Developments in the field, 2016 & 2017
    • 3.3.4. Global Translational Regenerative Medicine Market - Current Advancement in the field, 2016 & 2017
    • 3.3.5. Global Translational Regenerative Medicine Market - Current Key Approvals in the field, 2017

4. Stem Cell Therapies: Leading Applications, 2017-2027

  • 4.1. The Global Market for Stem Cell Therapies, 2016 and 2017
    • 4.1.1. Stem Cell Therapies: Currently Available Therapies
    • 4.1.2. Haematopoietic Stem Cell Transplantation(HSCT)
      • 4.1.2.1. HSCT for the Treatment of Multiple Sclerosis - A Possible Cure?
    • 4.1.3. Stem Cell Orthobiologics
  • 4.2. Stem Cell Therapies: Global Market Forecast 2017-2027
  • 4.3. AlloStem(AlloSource)
  • 4.4. Osteocel Plus(NuVasive)
    • 4.4.1. Osteocel Plus: Sales Forecast 2017-2027
  • 4.5. Trinity ELITE and Trinity Evolution(Orthofix)
    • 4.5.1. Trinity ELITE and Trinity Evolution: Sales Forecast, 2017-2027
  • 4.6. PureGen(AlphaTec Spine)
  • 4.7. Other Approved Stem Cell Therapy Products, 2015
    • 4.7.1. Cartistem(Medipost)
    • 4.7.2. Cupistem(Anterogen)
    • 4.7.3. Hearticellgram-AMI(Pharmicell)
    • 4.7.4. TEMCELL/ Prochymal/ Remestemcel-L(Mesoblast)
      • 4.7.4.1. TEMCELL/ Prochymal(Remestemcel-L): Sales Forecast 2017-2027
  • 4.8. Development Pipeline for Stem Cell Therapies, 2017-2027
    • 4.8.1. Late-Stage Pipeline for Stem Cell Therapies, 2015
      • 4.8.1.1. StemEx and NiCord(Gamida Cell)
        • 4.8.1.1.1. StemEx Shows Improved Survival at 100 Days - but FDA Wants Another Clinical Trial
      • 4.8.1.2. Copper Chelator Based Technology
      • 4.8.1.3. NiCord
        • 4.8.1.3.1. NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
        • 4.8.1.3.2. NAM Technology Platform
      • 4.8.1.4. Mesenchymal Precursor Cell Therapies(Mesoblast)
      • 4.8.1.5. Adult Autologous CD34+ Cells(Baxter)
      • 4.8.1.6. MyoCell(U.S. Stem Cell Inc.)
      • 4.8.1.7. Adipocell(Bioheart)
      • 4.8.1.8. Cx601(TiGenix)
      • 4.8.1.9. Adipose-Derived Stem Cells(Cytori Therapeutics)
      • 4.8.1.10. Stempeucel(Stempeutics Research)
      • 4.8.1.11. C-Cure(Cardio3 BioSciences)
      • 4.8.1.12. Other Late-Stage Stem Cell Therapies
    • 4.8.2. Diabetes and Stem Cell Therapy
      • 4.8.2.1. Mesenchymal Precursor Cells(Mesoblast)
      • 4.8.2.2. VC-01(ViaCyte Inc)
        • 4.8.2.2.1. Clinical Development Efforts for VC-01 for the Treatment of Diabetes
    • 4.8.3. Cardiovascular Disease and Stem Cell Therapy
      • 4.8.3.1. Endometrial Regenerative Cells(MediStem, Intrexon)
      • 4.8.3.2. AMR-001(Caladrius Biosciences)
      • 4.8.3.3. CAP-1002(Capricor)
    • 4.8.4. Stem Cell Therapy in Cancer
      • 4.8.4.1. CLT-008(Cellerant Therapeutics)
      • 4.8.4.2. OncoCyte/BioTime - Targeting Cancer with Gene and Stem Cell Therapy
    • 4.8.5. Stem Cell Therapy for Central Nervous System(CNS) Conditions
      • 4.8.5.1. NurOwn(BrainStorm Cell Therapeutics)
        • 4.8.5.1.1. Clinical Development Efforts for NurOwn, 2015
      • 4.8.5.2. NSI-566(Neuralstem)
      • 4.8.5.3. NSI-189(Neuralstem)
      • 4.8.5.4. MultiStem(Athersys)
      • 4.8.5.5. PDA-001(Cenplacel-L, Celgene)
      • 4.8.5.6. ALD-401(Cytomedix)
      • 4.8.5.7. ReN001(ReNeuron)
    • 4.8.6. Stem Cell Therapy for Eye Diseases
      • 4.8.6.1. MA09-hRPE(Ocata Therapeutics)
      • 4.8.6.2. HuCNS-SC(StemCells Inc.)
      • 4.8.6.3. Collaboration and License Agreement Between Pfizer And The London Project to Cure Blindness
  • 4.9. ChondroCelect(TiGenix BV)
  • 4.10. Stem Cells Therapy Market: Drivers and Restraints 2017-2027

5. Tissue Engineering Therapies: Leading Applications, 2017-2027

  • 5.1. The Global Market for Tissue Engineered Therapies, 2016
    • 5.1.1. Tissue Engineering Therapies: Currently Available Therapies
  • 5.2. Tissue Engineering Therapies: Global Market Forecast 2017-2027
  • 5.3. Tissue Engineering in Wound Repair and Healing
    • 5.3.1. Apligraf(Organogenesis)
      • 5.3.1.1. Apligraf: Historical Sales Analysis
      • 5.3.1.2. Apligraf: Sales Forecast 2017-2027
    • 5.3.2. BioDfence and BioDfactor(BioD)
    • 5.3.3. CureXcell(MacroCure)
    • 5.3.4. Dermagraft(Organogenesis)
      • 5.3.4.1. Dermagraft(Organogenesis): Sales Forecast 2017-2027
    • 5.3.5. Epifix(MiMedx)
      • 5.3.5.1. Epifix(MiMedx): Sales Forecast 2017-2027
    • 5.3.6. Epicel(Vericel)
    • 5.3.7. Grafix(Osiris Therapeutics)
    • 5.3.8. MySkin and CyroSkin(Regenerys)
    • 5.3.9. ReCell(Avita Medical)
      • 5.3.9.1. ReCell(Avita Medical): Sales Forecast 2017-2027
  • 5.4. Tissue Engineering for Cartilage Repair
    • 5.4.1. Autologous Chondrocyte Implantation(ACI)
    • 5.4.2. Carticel(Vericel Corp.)
    • 5.4.3. ChondroCelect(TiGenix, Sobi Partners)
    • 5.4.4. DeNovo NT(Zimmer)
    • 5.4.5. MACI(Vericel Corp.)
  • 5.5. Other Available Tissue Engineering Therapies
    • 5.5.1. Autologous Cultured Cell and Tissue Products(Japan Tissue Engineering Co.)
    • 5.5.2. Gintuit(Organogenesis)
    • 5.5.3. LAVIV(azficel-T),(Fibrocell Science)
    • 5.5.4. Acellular Tissue Engineering Products
  • 5.6. Tissue Engineering: Development Pipeline, 2017-2027
    • 5.6.1. Pipeline Products for Autologous Chondrocyte Implantation
    • 5.6.2. Tissue Engineering for Skin
    • 5.6.3. Tissue Engineering for Liver Diseases
      • 5.6.3.1. Extracorporeal Bio-Artificial Liver Therapy(Vital Therapies)
    • 5.6.4. Tissue Engineering for Cardiovascular Disease
    • 5.6.5. Tissue Engineering for Eye Diseases
  • 5.7. Future Prospects for Organ Transplantation and Tissue Engineering
  • 5.8. Tissue Engineered Products Market: Drivers and Restraints 2017-2027

6. Gene Therapies: Leading Applications, 2017-2027

  • 6.1. The Global Market for Gene Therapies, 2016
  • 6.2. Gene Therapies: Global Market Forecast 2017-2027
  • 6.3. Currently Available Gene Therapy Products
    • 6.3.1. Gendicine(Benda Pharmaceutical)
    • 6.3.2. Oncorine(Shanghai Sunway Biotech)
    • 6.3.3. Neovasculgen(Human Stem Cells Institute)
      • 6.3.3.1. Neovasculgen(HSCI): Sales Forecast 2017-2027
    • 6.3.4. Glybera(UniQure)
      • 6.3.4.1. Glybera: Sales Forecast 2017-2027
    • 6.3.5. IMLYGIC(talimogene laherparepvec) -(Amgen)
      • 6.3.5.1. Clinical Trials and Development Efforts for IMLYGIC
      • 6.3.5.2. Talimogene Laherparepvec(IMLYGIC) - Sales Forecast 2017-2027
  • 6.4. Development Pipeline for Gene Therapies, 2017-2027
    • 6.4.1. Late-Stage Pipeline Gene Therapies, 2015
      • 6.4.1.1. Collategene(beperminogene perplasmid, AMG0001) -(AnGes MG/Vical)
      • 6.4.1.2. ProstAtak(AdV-tk) -(Advantagene)
      • 6.4.1.3. Trinam(taberminogene vadenovec) -(Ark Therapeutics)
      • 6.4.1.4. AAV2-hRPE65v2(Spark Therapeutics)
      • 6.4.1.5. CG0070(Cold Genesys)
    • 6.4.2. Gene Therapy for Use in the Treatment of Diabetes
    • 6.4.3. Gene Therapy Directed At Oncology Indications
    • 6.4.4. Gene Therapy Directed at Neurological Diseases
    • 6.4.5. Gene Therapy Directed at Tackling Haemophilia B
  • 6.5. Gene Therapy Market: Drivers and Restraints 2017-2027

7. Leading National Markets for Translational Regenerative Medicine, 2017-2027

  • 7.1. The Translational Regenerative Medicine Market by Region
    • 7.1.1. The Global Distribution of Translational Regenerative Medicine in 2016 and 2017
  • 7.2. Leading National Markets: Forecast 2017-2027
    • 7.2.1. Changing Market Shares by Region, 2017-2027
  • 7.3. Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2017-2027
  • 7.4. United States: The Largest Translational Regenerative Medicine Market
    • 7.4.1. US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2017-2027
    • 7.4.2. US Translational Regenerative Medicine Market: Market Forecast 2017-2027
    • 7.4.3. The Regulatory Framework for Regenerative Medicine in the US
    • 7.4.4. The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
    • 7.4.5. How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
  • 7.5. Europe: A Fragmented Regenerative Medicine Market
    • 7.5.1. European Regenerative Medicine Market: Market Drivers and Restraints, 2017-2027
    • 7.5.2. European Regenerative Medicine Market: Market Forecast 2017-2027
    • 7.5.3. Europe's Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
    • 7.5.4. Regulation of Regenerative Medicine in the European Union
    • 7.5.5. UK: A Leading Research Centre for Regenerative Medicine in Europe
      • 7.5.5.1. Regulation of Stem Cell Research in the UK
    • 7.5.6. Russia: Rising Interest in Regenerative Medicine Research
  • 7.6. Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
    • 7.6.1. Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2017-2027
    • 7.6.2. Asia-Pacific Regenerative Medicine Market: Market Forecast 2017-2027
    • 7.6.3. Australia: Encouraging Translational Regenerative Medicine
    • 7.6.4. China: Encouraging Stem Cell R&D
      • 7.6.4.1. Government Intervention into TRM Research in China
      • 7.6.4.2. Regulation of Stem Cell Research in China
      • 7.6.4.3. Commercialisation of Gene Therapy and Tissue Engineering Products in China
      • 7.6.4.4. Medical Tourism Impacting Market Growth for Regenerative Medicine in China
    • 7.6.5. Japan: Difficulty in Translating Research into Commercialisation
      • 7.6.5.1. Research Funding: A Major Determinant of Growth in Japan's Regenerative Medicine
      • 7.6.5.2. Government Interventions in Promoting Stem Cell Research in Japan
      • 7.6.5.3. Regulation of Regenerative Medicine in Japan
      • 7.6.5.4. Accelerating Approvals of Regenerative Medicine Products in Japan
    • 7.6.6. India: An Emerging Market for Regenerative Medicine
      • 7.6.6.1. Efforts in Stem Cell Research in India
      • 7.6.6.2. Unclear Guidelines Hindering Progression of Gene Therapy Research in India
    • 7.6.7. South Korea: First to Approve Stem Cell Treatments
      • 7.6.7.1. A Regeneration In South Korea's Stem Cell Research Efforts
  • 7.7. Rest of the World: Regenerative Medicine Conquering New Territories and Booming
    • 7.7.1. Rest of the World Regenerative Medicine Market: Market Forecast 2017-2027

8. Leading Companies in the Translational Regenerative Medicine Market, 2017-2027

  • 8.1. Translational Regenerative Medicine: A Hotbed for Innovation
  • 8.2. Alphatec Spine
    • 8.2.1. Alphatec Spine: Financial and Performance Analysis, 2011-2015
    • 8.2.2. Alphatec Spine's Shifting Focus from Regenerative Medicine to Medical Devices
  • 8.3. Anterogen
    • 8.3.1. Anterogen: Pipeline Analysis, 2015
  • 8.4. Athersys
    • 8.4.1. Athersys: Financial and Performance Analysis, 2011-2015
    • 8.4.2. Athersys: Pipeline Analysis, 2015
      • 8.4.2.1. MultiStem Technology - Potential Treatment for a Range of Diseases
  • 8.5. Avita Medical
    • 8.5.1. Avita Medical: Historical Financial and Performance Analysis, 2013-2015
    • 8.5.2. Avita Medical: Regenerative Medicine Portfolio, 2015
    • 8.5.3. Avita Medical: Pipeline Analysis, 2015
  • 8.6. AxoGen
    • 8.6.1. AxoGen: Historical Financial and Performance Analysis, 2011-2015
    • 8.6.2. AxoGen: Regenerative Medicine Portfolio, 2015
    • 8.6.3. AxoGen: Pipeline Analysis, 2015
  • 8.7. Medipost
    • 8.7.1. Medipost: Historical Financial and Performance Analysis, 2011-2015
    • 8.7.2. Medipost: Regenerative Medicine Portfolio, 2015
    • 8.7.3. Medipost: Pipeline Analysis, 2015
  • 8.8. Mesoblast
    • 8.8.1. Mesoblast Product Portfolio, 2015
    • 8.8.2. Mesoblast: Historical Financial and Performance Analysis, 2010-2015
    • 8.8.3. Mesoblast: Pipeline Analysis, 2015
      • 8.8.3.1. NeoFuse
      • 8.8.3.2. Chondrogen
      • 8.8.3.3. Prochymal / TEMCELL
      • 8.8.3.4. Other Recent Pipeline Acquisitions by Mesoblast
  • 8.9. NuVasive
    • 8.9.1. NuVasive Product Portfolio, 2015
    • 8.9.2. NuVasive: Historical Financial and Performance Analysis, 2011-2015
    • 8.9.3. NuVasive: Pipeline Analysis, 2015
  • 8.10. Ocata Therapeutics(Acquired by Astellas Pharma Inc.)
    • 8.10.1. Ocata Therapeutics: Historical Financial and Performance Analysis, 2011-2015
    • 8.10.2. Ocata Therapeutics: Pipeline Analysis, 2015
      • 8.10.2.1. Retinal Pigment Epithelial Cell Therapy
    • 8.10.3. Ocata's Other Therapeutic Platforms
  • 8.11. Organogenesis
    • 8.11.1. Organogenesis RM Portfolio, 2015
    • 8.11.2. Organogenesis: Pipeline Analysis, 2015
  • 8.12. Osiris Therapeutics
    • 8.12.1. Osiris Therapeutics: RM Portfolio, 2015
    • 8.12.2. Osiris Therapeutics: Historical Financial and Performance Analysis, 2011-2015
    • 8.12.3. Osiris Therapeutics: Pipeline Analysis, 2015
  • 8.13. Pharmicell
    • 8.13.1. Pharmicell: Historical Financial and Performance Analysis, 2011-2015
    • 8.13.2. Pharmicell: Pipeline Analysis, 2015
  • 8.14. Regenerys
    • 8.14.1. Regenerys: RM Portfolio, 2015
    • 8.14.2. Regenerys: Pipeline Analysis, 2015
  • 8.15. TiGenix
    • 8.15.1. TiGenix: Historical Financial and Performance Analysis, 2011-2015
    • 8.15.2. TiGenix: Pipeline Analysis, 2015
  • 8.16. UniQure
    • 8.16.1. UniQure: Recent Major Acquisition and Collaboration
    • 8.16.2. UniQure: Pipeline Analysis, 2015
  • 8.17. Vericel Corporation(Formerly Aastrom Biosciences, Inc.)
    • 8.17.1. Vericel's Acquisition of Sanofi's Regenerative Medicine Business
    • 8.17.2. Vericel: Historical Financial and Performance Analysis, 2011-2015
    • 8.17.3. Vericel Regenerative Medicine Portfolio, 2015
    • 8.18.4. Vericel: Pipeline Analysis, 2015
      • 8.17.2.1. The ixCELL-DCM Clinical Trial

9. Qualitative Analysis for the Global Translational Regenerative Medicine Market, 2017-2027

  • 9.1. Market Factors Influencing the Translational Regenerative Medicine Market
  • 9.2. SWOT Analysis of the Translational Regenerative Medicine Market, 2017-2027
  • 9.3. Strengths
    • 9.3.1. Improvements in Regulatory Frameworks
    • 9.3.2. Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
    • 9.3.3. Strong Support from Governments in Multiple Regions
    • 9.3.4. Increasing Ease of Product Commercialisation and Market Access
  • 9.4. Weaknesses
    • 9.4.1. The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
    • 9.4.2. Lack of Funding from Venture Capital
    • 9.4.3. The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
    • 9.4.4. Successful Commercialisation of TRM Products Requires New Business Models
  • 9.5. Opportunities
    • 9.5.1. 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
    • 9.5.2. Medical Tourism May Stimulate Standardisation and Drive Market Growth
    • 9.5.3. Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
  • 9.6. Threats
    • 9.6.1. Ethical Concerns Limiting R&D in Regenerative Medicine
    • 9.6.2. Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies
    • 9.6.3. Rate of Scientific Progress - A Major Determinant of TRM Market Growth
    • 9.6.4. Restraints on Reimbursement May Slow Growth
  • 9.7. Porter's Five Force Analysis of the Translational Regenerative Medicine Market, 2017-2027
    • 9.7.1. Threat of New Entrants
    • 9.7.2. Threat of Substitutes
    • 9.7.3. Power of Suppliers
    • 9.7.4. Power of Buyers
    • 9.7.5. Rivalry among Competitors

10. Conclusions

  • 10.1. Overview of Current Market Conditions and Market Forecast, 2017-2027
  • 10.2. Leading Regenerative Medicine Segments in 2016 and 2017
  • 10.3. Leading Regions in the Translational Regenerative Medicine Market in 2016 And 2017
  • 10.4. Future Outlook for the Various Sectors within TRM, 2017-2027
  • 10.5. R&D Pipeline Products Crucial to Future Market Growth
  • 10.6. What Does the Future Hold for Regenerative Medicine?
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1(Sample) Global Translational Regenerative Medicine Market: Market Forecast($m, AGR% and CAGR%) by Segment, 2016-2021
  • Table 2.1: European Union Definitions of Regenerative Medicine Products, 2015
  • Table 2.2: Potency and Source of Stem Cells, 2016
  • Table 2.3: Germ Layers and Their Associated Types of Cells and Organs, 2016
  • Table 2.4: Major Types of Stem Cells and Their Properties, 2016
  • Table 2.5: Terminology for Stem Cell Donor-Types, 2016
  • Table 2.6: Clinical Trial Phases, 2016
  • Table 3.1: The Global Translational Regenerative Medicine Market: Revenue($m) and Market Shares(%) by Sector, 2016 and 2017
  • Table 3.2: The Global Translational Regenerative Medicine Market: Market Forecast($m, AGR% and CAGR%) by Sector, 2016-2021
  • Table 3.3: The Global Translational Regenerative Medicine Market: Market Forecast($m, AGR% and CAGR%) by Sector, 2022-2027
  • Table 3.4: The Global Translational Regenerative Medicine Market Forecast: CAGR(%) by Sector, 2016-2021, 2022-2027 and 2016-2027
  • Table 3.5: The Global Translational Regenerative Medicine Market: Revenue($m) by Sector, 2016, 2021 and 2027
  • Table 3.6: The Global Translational Regenerative Medicine Market: Market Share(%) by Sector, 2016, 2021 and 2027
  • Table 4.1: Selected Stem Cell Products Currently Available On the Market, 2016
  • Table 4.2: Stages of Osteogenesis, 2016
  • Table 4.3: Global Stem Cell Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 4.4: Global Stem Cell Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 4.5: Osteocel Plus Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.6: Osteocel Plus Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2027
  • Table 4.7: Trinity ELITE Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 4.8: Trinity ELITE Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 4.9: TEMCELL / Prochymal Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 4.10: TEMCELL / Prochymal Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 4.11: Stem Cell Therapy Pipeline: Therapies in Development, Clinical Trials
  • Table 4.12: Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
  • Table 5.1: Selected Tissue Engineering Products Currently Available on the Market, 2015
  • Table 5.2: Global Tissue Engineering Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 5.3: Global Tissue Engineering Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 5.4: Apligraf Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 5.5: Apligraf Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 5.6: Dermagraft Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 5.7: Dermagraft Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 5.8: Epifix Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 5.9: Epifix Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 5.10: ReCell Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 5.11: ReCell Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 5.12: Tissue Engineering Pipeline: Therapies in Development, Clinical Trials
  • Table 5.13: Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2015
  • Table 6.1: Currently Available Gene Therapy Products, 2015
  • Table 6.2: Global Gene Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 6.3: Global Gene Therapies Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 6.4: Neovasculgen Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 6.5: Neovasculgen Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 6.6: Glybera Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 6.7: Glybera Sales Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 6.8: Amgen: Gene Therapy Clinical Trials, 2015
  • Table 6.9: Talimogene Laherparepvec(IMLYGIC) Sales Forecast($m, AGR% and CAGR%), 2016-2021
  • Table 6.10: Talimogene Laherparepvec(IMLYGIC) Sales Forecast($m, AGR% and CAGR%), 2022-2027
  • Table 6.11: Gene Therapy Pipeline: Therapies in Development, Clinical Trials
  • Table 6.12: Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015
  • Table 6.13: Advantegene: Gene Therapy Clinical Trials, 2015
  • Table 6.14: Spark Therapeutics: Gene Therapy Clinical Trials, 2015
  • Table 6.15: Recent Developments in Gene Therapy for Use in Diabetes
  • Table 6.16: Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2015
  • Table 7.1: The Global Translational Regenerative Medicine Market: Market Size($m) and Market Share(%) by Region, 2016 and 2017
  • Table 7.2: Global Translational Regenerative Medicine Market: Market Forecast($m), AGR(%) and CAGR(%) by Region, 2016-2021
  • Table 7.3: Global Translational Regenerative Medicine Market: Market Forecast($m), AGR(%) and CAGR(%) by Region, 2022-2027
  • Table 7.4: Global Translational Regenerative Medicine Market: CAGR(%) by Region, 2016-2021, 2022-2027, 2016-2027
  • Table 7.5: Global Translational Regenerative Medicine Market: Market Share(%) by Region, 2016, 2021 and 2027
  • Table 7.6: US Translational Regenerative Medicine Market Forecast: Revenue($m), Market Share(%) and CAGR(%), 2016, 2021 and 2027
  • Table 7.7: US Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 7.8: US Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 7.9: European Translational Regenerative Medicine Market Forecast: Revenue($m), Market Share(%) and CAGR(%), 2016, 2021 and 2027
  • Table 7.10: European Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 7.11: European Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 7.12: Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue($m), Market Share(%) and CAGR(%), 2016-2027
  • Table 7.13: Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 7.14: Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 7.15: Rest of the World Translational Regenerative Medicine Market Forecast: Revenue($m), Market Share(%) and CAGR(%), 2016-2027
  • Table 7.16: Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2016-2021
  • Table 7.17: Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue($m), AGR(%) and CAGR(%), 2022-2027
  • Table 8.1: Alphatec Spine: Historical Sales($m) and Operating Profit / Loss($m), 2011-2015
  • Table 8.2: Alphatec Spine: Regenerative Medicine Clinical Trials, 2015
  • Table 8.3: Anterogen: Regenerative Medicine Clinical Trials, 2015
  • Table 8.4: Athersys: Historical Sales($m) 2011-2015
  • Table 8.5: Athersys: Historical Expenditure and Losses($m) 2011-2015
  • Table 8.6: Athersys: Regenerative Medicine Clinical Trials, 2015
  • Table 8.7: Avita Medical: Historical Sales($m, AUD m) and Net Loss($m, AUD m), 2011-2015
  • Table 8.8: Avita Medical: Regenerative Medicine Clinical Trials, 2015
  • Table 8.9: AxoGen: Historical Sales($m) and Net Loss($m), 2011-2015
  • Table 8.10: AxoGen: Regenerative Medicine Clinical Trials, 2015
  • Table 8.11: Medipost: Historical Sales($m, mil.KRW), Net Income($m, mil.KRW) and Revenue Growth(%) 2011-2015
  • Table 8.12: Medipost: Historical Sales(mil.KRW), Net Income($m, mil.KRW) and Revenue Growth(%) 2011-2015
  • Table 8.13: Medipost: Regenerative Medicine Clinical Trials, 2015
  • Table 8.14: Mesoblast: Historical Sales($m, AUD m), 2011-2015
  • Table 8.15: Mesoblast: Regenerative Medicine Clinical Trials, 2015
  • Table 8.16: NuVasive: Historical Sales($m) and Net Income(Profits and Losses)($m), 2011-2015
  • Table 8.17: NuVasive: Regenerative Medicine Clinical Trials, 2015
  • Table 8.18: Ocata Therapeutics: Historical Sales($thousand) and Gross Income($thousand), 2011-2015
  • Table 8.19: Ocata Therapeutic: Regenerative Medicine Clinical Trials, 2015
  • Table 8.20: Organogenesis: Regenerative Medicine Clinical Trials, 2015
  • Table 8.21: Osiris Therapeutics: Revenue($m) and Net Income($m), 2011-2015
  • Table 8.22: Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2015
  • Table 8.23: Pharmicell: Historical Sales($m, mil.KRW) and Net Income($m, mil.KRW), 2011-2015
  • Table 8.24: Regenerys: Regenerative Medicine Clinical Trials, 2015
  • Table 8.25: TiGenix: Historical Sales(€m, $m) and Net Income(€m, $m), 2011-2015
  • Table 8.26: TiGenix: Regenerative Medicine Clinical Trials, 2015
  • Table 8.27: UniQure: Regenerative Medicine Clinical Trials, 2015
  • Table 8.28: Vericel: Historical Sales($m and AGR%), 2011-2015
  • Table 8.29: Vericel: Sales by Product($m) and Revenue Share(%), 2013-2014
  • Table 8.30: Vericel Corporation: Regenerative Medicine Clinical Trials, 2015
  • Table 9.1: SWOT Analysis of the Global Translational Regenerative Medicine Market, 2017-2027
  • Table 10.1: Global Translational Regenerative Medicine: Market Forecast($m, CAGR%), 2016, 2022, 2027
  • Table 10.2: Global Translational Regenerative Medicine Market: Revenue($m) and Market Shares(%) by Sector, 2016
  • Table 10.3: Global Translational Regenerative Medicine Market: Revenue($m) and Market Shares(%) by Region, 2016, 2022 and 2027
  • Table 10.4: Global Translational Regenerative Medicine: Market Forecast($m) by Sector, 2016, 2022 and 2027
  • Table 10.5: Global Translational Regenerative Medicine Market: Products In Late Stage Development, 2015

List of Figures

  • Figure 1.1: Global Translational Regenerative Medicine Market: Submarkets, 2016
  • Figure 2.1: Brief History of Stem Cell Research, 1900-2016
  • Figure 2.2: Examples of FDA-Approved Tissue Engineering Products
  • Figure 2.3: Brief History of Tissue Engineering, 1900-2015
  • Figure 2.4: Brief History of Gene Therapy, 1970-2015
  • Figure 3.1: The Global Translational Regenerative Medicine Market: Revenue($m) by Sector, 2016 and 2017
  • Figure 3.2: The Gene Therapy Market: Revenue($m), 2016 and 2017
  • Figure 3.3: The Global Translational Regenerative Medicine Market Market Forecast: Revenue($m) and AGR(%),2016-2027
  • Figure 3.4: The Global Translational Regenerative Medicine Market Forecast: CAGR(%) by Sector, 2016-2021
  • Figure 3.5: The Global Translational Regenerative Medicine Market Forecast: CAGR(%) by Sector, 2022-2027
  • Figure 3.6: The Global Translational Regenerative Medicine Market Forecast: CAGR(%) by Sector, 2016-2027
  • Figure 3.7: The Global Translational Regenerative Medicine Market: Revenue($m) by Sector, 2016, 2021 and 2027
  • Figure 3.8: The Global Translational Regenerative Medicine Market: Market Share(%) by Sector, 2016
  • Figure 3.9: The Global Translational Regenerative Medicine Market: Market Share(%) by Sector, 2021
  • Figure 3.10: The Global Translational Regenerative Medicine Market: Market Share(%) by Sector, 2027
  • Figure 4.1: Global Stem Cell Therapies Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 4.2: Osteocel Plus Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 4.3: Trinity ELITE Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 4.4: TEMCELL / Prochymal Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.1: Global Tissue Engineering Therapies Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.2: Apligraf Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.3: Dermagraft Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.4: Epifix Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.5: ReCell Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 5.6: Tissue Engineered Therapy Products: Drivers and Restraints, 2017-2027
  • Figure 6.1: Global Gene Therapies Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 6.2: Neovasculgen Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 6.3: Glybera Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 6.4: Talimogene Laherparepvec(IMLYGIC) Sales Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 6.5: Gene Therapy Products: Market Drivers and Restraints, 2017-2027
  • Figure 7.1: The Global Translational Regenerative Medicine Market: Market Size($m) by Region, 2016 and 2017
  • Figure 7.2: Asia-Pacific, Europe, US, and ‘Rest of the World' Translational Regenerative Medicine Market: Market Forecast($m), 2016-2027
  • Figure 7.3: Global Translational Regenerative Medicine Market: CAGR(%) by Region, 2016-2021
  • Figure 7.4: Global Translational Regenerative Medicine Market: CAGR(%) by Region, 2022-2027
  • Figure 7.5: Global Translational Regenerative Medicine Market: CAGR(%) by Region, 2016-2027
  • Figure 7.6: Global Translational Regenerative Medicine Market: Market Share(%) by Region, 2016
  • Figure 7.7: Global Translational Regenerative Medicine Market: Market Share(%) by Region, 2021
  • Figure 7.8: Global Translational Regenerative Medicine Market: Market Share(%) by Region, 2027
  • Figure 7.9: US Translational Regenerative Medicine: Market Drivers and Restraints, 2017-2027
  • Figure 7.10: US Translational Regenerative Medicine Market Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 7.11: European Translational Regenerative Medicine: Market Drivers and Restraints, 2017-2027
  • Figure 7.12: European Translational Regenerative Medicine Market Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 7.13: Asia-Pacific Translational Regenerative Medicine: Market Drivers and Restraints, 2017-2027
  • Figure 7.14: Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue($m) and AGR(%), ss2016-2027
  • Figure 7.15: Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue($m) and AGR(%), 2016-2027
  • Figure 8.1: Alphatec Spine: Historical Sales($m) and Operating Loss($m), 2011-2015
  • Figure 8.2: Athersys: Historical Sales($m) 2011-2015
  • Figure 8.3: Athersys: Historical Revenue, Expenditure and Losses($m) 2011-2015
  • Figure 8.4: Avita Medical: Historical Sales($m, AUD m) and Net Loss($m), 2011-2015
  • Figure 8.5: AxoGen: Historical Sales($m) and Net Loss($m), 2011-2015
  • Figure 8.6: Medipost: Historical Sales($m, mil.KRW) and Net Income($m, mil.KRW), 2010-2014
  • Figure 8.7: Medipost: Revenue Share by Business Area(%), 2013
  • Figure 8.8: Medipost: Revenue Share by Business Area(%), 2014
  • Figure 8.9: Medipost: Revenue Share by Business Area(%), 2015
  • Figure 8.10: Mesoblast: Historical Sales(AUD m), 2011-2015
  • Figure 8.11: NuVasive: Historical Sales and Net Income(Profits and Losses)($m), 2011-2015
  • Figure 8.12: Ocata Therapeutics: Historical Sales($m) and Gross Income($thousand), 2011-2015
  • Figure 8.13: Osiris Therapeutics: Revenue($m) and Net Income($m), 2011-2015
  • Figure 8.14: Pharmicell: Historical Sales(mil.KRW) and Net Income(mil.KRW), 2011-2015
  • Figure 8.15: TiGenix: Historical Sales($m) and Net Income($m), 2011-2015
  • Figure 8.16: Vericel: Historical Sales($m), 2011-2015(Limited Scale)
  • Figure 8.17: Vericel: Revenue Contribution by Product(%) 2014
  • Figure 9.1: Porter's Five Force Analysis of the Translational Regenerative Medicine Market, 2016
  • Figure 10.1: Global Translational Regenerative Medicine: Market Forecast($m), 2016, 2022 and 2027
  • Figure 10.2: Global Translational Regenerative Medicine Market: Market Share(%) by Sector, 2016
  • Figure 10.3: Global Translational Regenerative Medicine: Market Forecast($m) by Sector, 2016-2027

Companies Listed

  • Advanced BioHealing
  • Advanced Tissue Sciences
  • Advantagene
  • AlloSource
  • AlphaTec Spine
  • Amedica
  • Amgen
  • Amorcyte
  • Amorepacific Group
  • AnGes MG
  • Angioblast Systems
  • Anika Therapeutics
  • Anterogen
  • Apceth
  • Arcarios B.V
  • Ark Therapeutics
  • Athersys Inc
  • Avita Medical
  • AxoGen
  • Baxter
  • Beike Biotechnology
  • Benda Pharmaceutical
  • BioD
  • Bioheart
  • BioMed Realty Trust, Inc
  • BioSante Pharmaceuticals
  • BioTime
  • BioTissue AG
  • BioVex Inc
  • Blackstone Medical
  • BrainStorm Cell Therapeutics
  • Caladrius Biosciences
  • California Stem Cell Inc
  • Capricor
  • Cardio3BioSciences
  • Celgene
  • Cell Targeting
  • CellCo Tec
  • Cellerant Therapeutics
  • Cephalon
  • Ceregene
  • CHA Biotech
  • Chiesi Farmaceutici
  • Cipla
  • Co.don AG
  • Cold Genesys
  • Cook Biotech Inc
  • Cytomedix
  • Cytori Therapeutics
  • Daiichi Sankyo
  • DePuy Mitek(Johnson & Johnson)
  • FibroCell Science
  • Gamida Cell Ltd
  • Genzyme Corporation(Sanofi)
  • Histogenics
  • Humacyte
  • Human Stem Cell Institute
  • Insulete Inc
  • Interxon Corporation
  • ISTO Technologies
  • Janssen Biotech Inc
  • Japan Tissue Engineering Co
  • JCR Pharmaceuticals
  • Johnson & Johnson
  • Kinetic Concept Inc
  • LecTec Corporation
  • Lincoln Park Capital
  • Lonza
  • MacroCure
  • Medipost
  • Medtronic
  • Mesoblast
  • Mitsubishi Tanabe
  • Myriad Genetics
  • Neostem
  • Neuralstem
  • Nippon Zoki Pharmaceuticals
  • NuVasive
  • Ocata Therapeutics
  • OncoCyte
  • Organovo
  • Orphan Biovitrum AB(Sobi)
  • Orthofix
  • Orteq Ltd.
  • Osiris Therapeutics
  • Oxford BioMedica
  • Parcell Laboratories
  • Pfizer
  • Pharmicell
  • Regenerys
  • Reliance Life Sciences
  • ReNeuron
  • RTI Surgical
  • Rusnano Corporation
  • Sangamo Biosciences
  • Sanofi
  • Shanghai Sunway Biotech
  • Shenzhen Sibiono GeneTech
  • Shire
  • Singapore General Hospital
  • Skye Orthobiologics
  • Smith & Nephewbv
  • Sobi Partners
  • Spark Therapeutics
  • StemCells Inc.
  • Stempeutics Research
  • Stratatech Corporation
  • TCA Cellular Therapy
  • Tengion Inc
  • Teva Pharmaceuticals
  • TiGenix
  • UniQure
  • U.S. Stem Cell Inc.
  • Vericel Corporation
  • Viacyte Inc
  • Vital Therapies
  • WKD Holding Oy
  • Xcellerex
  • Xenetic Biosciences
  • Zimmer

List of Organisations Mentioned in the Report

  • Arthritis Research UK
  • Associazione Infermieristica per lo Studio delle Lesioni Cutanee(AISLeC) [China]
  • Australian Regenerative Medicine Institute
  • Australian Sports Anti-Doping Authority(ASADA)
  • Biomedical Advanced Research and Development Authority(BARDA)
  • British Heart Foundation [UK]
  • California Institute of Regenerative Medicine(CIRM)
  • Cambridge Stem Cell Biology Institute [UK]
  • Case Western Reserve University
  • Catalan Institution for Research and Advanced Studies
  • Center for Biologics Evaluation and Research(CBER) [US]
  • CHA General Hospital [Korea]
  • Cryocenter Saint Petersburg
  • Drugs Controller General of India(DCGI)
  • European Group for Blood and Marrow Transplantation(EBMT)
  • European Medicines Agency
  • Food and Drugs Agency(FDA) [US]
  • Haute Autorité de santé [France]
  • Heriot-Watt University
  • Human Fertilisation and Embryology Authority(HFEA)
  • Institute of Biomedical Research and Innovation Hospital [Japan]
  • International Society for Stem Cell Research(ISSCR)
  • Karolinska Institute [Sweden]
  • Massachusetts General Hospital(MGH)
  • Mayo Clinic [US]
  • Medical Research Council [UK]
  • MiMedx
  • Ministry of Food and Drug Safety, MFDS) [Korea]
  • Ministry of Health, Labour and Welfare(MHLW) [Japan]
  • Ministry of Science and Technology [China]
  • Moorfields Eye Hospital
  • National Tissue Engineering Center(NTEC) [China]
  • New York Blood Center
  • Riken Center for Developmental Biology
  • RUSH University Medical Center [US]
  • Russian Ministry of Healthcare and Social Development
  • Scottish Centre for Regenerative Medicine
  • St. Jude's Children Research Hospital
  • State Food and Drug Administration(SFDA) [China]
  • SUNY Upstate Medical University
  • The Genetico Center [Russia]
  • The StemGen Organisation
  • Therapeutics Goods Administration(TGA) [Australia]
  • UH San Diego Sanford Stem Cell Clinical Center
  • UK Medicines and Healthcare Products Regulatory Agency(MHRA)
  • Universitat Autònoma de Barcelona [Spain]
  • University College London
  • University of Edinburgh MRC Centre for Regenerative Medicine [UK]
  • University of Massachusetts(UMass) Memorial Hospital
  • University of Modena Centre for Regenerative Medicine [Italy]
  • University of Wisconsin
  • US National Institute of Health
  • Wake Forest Institute
  • Wellcome Trust
  • World Health Organization
Back to Top